who we are
Kodiak Sciences is a clinical-stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases. We are thrilled to support Vista Center in its mission and are honored to contribute to efforts that empower individuals who are blind or visually impaired. We are a patient-focused company and are looking forward to deepening our roots in the local community while expanding our impact globally. We believe an incredible unmet need still exists—not just for patients, but for physicians and the healthcare system. Current anti-VEGF therapies can improve and sustain vision in patients for many years when dosed monthly or every other month during a clinical trial. But in the real world, patients are not seen or treated this often. Since current medicines only last in the eye for a relatively short time, the disease recurs between doses, leading to permanent vision loss starting just a few months after initiation of therapy outside of clinical trials. It’s a global epidemic of preventable blindness. The solution is to bring new science to the design and manufacture of next-generation retinal medicines so that the medicines can fit seamlessly into the lives of our patients and their caregivers. At Kodiak, we have been focused on this problem, and this unmet need since our inception as a company ten years ago. Our relationship with Vista Center is a continuation of our journey, one that connects us to the patients we are serving. It has been a privilege engaging with the Vista team and volunteering in the community.
Kodiak Sciences (Nasdaq: KOD) is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA.